Prolyl Endopeptidase Inhibitory Activity of 6-O-Palmitoyl L-Ascorbic Acid

  • Park, Yoon-Seok (College of Environment and Applied Chemistry and Plant Metabolism Research Center, Kyung Hee University) ;
  • Paik, Young-Sook (College of Environment and Applied Chemistry and Plant Metabolism Research Center, Kyung Hee University)
  • Published : 2006.09.30

Abstract

Prolyl endopeptidase (PEP, EC 3.4.21.26, also referred to as prolyl oligopeptidase) degrades proline containing, biologically active neuropeptides such as vasopressin, substance P and thyrotropin-releasing hormone by cleaving peptide bonds on carboxyl side of prolyl residue within neuropeptides of less than 30 amino acids. Evaluation of PEP levels in postmortem brains of Alzheimer's disease patients revealed significant increases in PEP activity. Therefore, a specific PEP inhibitor can be a good candidate of drug against memory loss. Upon our examination for PEP inhibitory activity from micronutrients, ascorbic acid (vitamin C) showed small but significant PEP inhibition (13% PEP inhibition at $8{\mu}g{\cdot}ml^{-1}$). Palmitic acid showed almost no PEP inhibition. However, 6-O-palmitoyl ascorbic acid ($\underline{1}$) showed 70% PEP inhibition at $8{\mu}g{\cdot}ml^{-1}$ indicating that hydrophobic portion of the compound $\underline{1}$ may facilitate the inhibitory effect. $IC_{50}$ value of compound $\underline{1}$ was $12.6{\pm}0.2{\mu}M$. The primary and secondary Lineweaver Burk and Dixon plots for compound $\underline{1}$ indicated that it is a non-competitive inhibitor with inhibition constant (Ki) value of $23.7{\mu}M$.

Keywords

References

  1. Cunningham, D. F. and O'Connor, B. (1997) Proline specific peptidase. Biochem. Biophys. Acta 1343, 160-186 https://doi.org/10.1016/S0167-4838(97)00134-9
  2. Walter, R., Shlank, H., Glass, J. D., Schwartz, I. L. and Kerenyi, T. D. (1971), Leucylglycinamide released from oxytocin by human uterine enzyme. Science 173, 827-829 https://doi.org/10.1126/science.173.3999.827
  3. Kalwant, S. and Porter, A. G.. (1991) Purification and characterization of human brain prolyl endopeptidase. Biochem. J. 276, 237-244 https://doi.org/10.1042/bj2760237
  4. Odaka, C., Mizuochi, T., Shirasawa, T., Morain, P. and Checler, F. (2002) Murine T cells expressing high activity of prolyl endopeptidase are susceptible to activation-induced cell death. FEBS Lett. 512, 163-167 https://doi.org/10.1016/S0014-5793(02)02249-4
  5. Aoyagi, T., Wada, T., Nagai, M., Kojima, F., Harada, S., Takeuchi, T., Takahashi, H., Hirokawa, K. and Tsumita, T. (1990) Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 46, 94-97 https://doi.org/10.1007/BF01955428
  6. Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten J. C., Hofman, A., Witteman, J. C. and Breteler, M. M. (2002) Dietary intake of antioxidants and risk of Alzheimer disease. J. Amer. Med. Assoc. 287, 3223-3229 https://doi.org/10.1001/jama.287.24.3223
  7. Markesbery, W. R. (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radical Bio. Med. 23, 134-147 https://doi.org/10.1016/S0891-5849(96)00629-6
  8. Parle, M. and Dhingra, D. (2003) Ascorbic acid: a promising memory-enhancer in mice. J. Pharmacol. 93, 129-135 https://doi.org/10.1254/jphs.93.129
  9. Frank, B. and Gupta, S. (2005) A review of antioxidants and Alzheimer's disease. Ann Clin. Psychiatr.17, 269-286 https://doi.org/10.1080/10401230500296428
  10. Morris, M. C., Beckett, L. A. and Scherr, P. A. (1998) Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alz. Dis. Assoc. Disord. 12, 121-126 https://doi.org/10.1097/00002093-199809000-00001
  11. Masaki, K. H., Losonczy, K. G., Izmirlian, G., Foley, D. J., Ross, G. W., Petrovitch, H., Havlik, R. and White, L. R. (2000) Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 54, 1265-1272 https://doi.org/10.1212/WNL.54.6.1265
  12. Duffy, S. J., Gokce, N., Holbrook, M., Huang, A., Frei, B., Keaney Jr, J. F. and Vita, J. A. (1999) Treatment of hypertension with ascorbic acid. The Lancet 354, 2048-2049 https://doi.org/10.1016/S0140-6736(99)04410-4
  13. Padayatty, S. J. and Levine, M. (2000) Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J. Am. Coll. Nutr. 19, 423-425 https://doi.org/10.1080/07315724.2000.10718941
  14. Yoshimoto, T., Walter, R. and Tsuru, D. (1980) Proline-specific endopeptidase from Flavobacterium. Purification and properties. J. Biol. Chem. 255, 4786-4792
  15. Park, Y.-S., Jang, H.-J., Lee, K.-H., Hahn, T.-R. and Paik, Y.-S. (2006) Prolyl endopeptidase inhibitory activity of unsaturated fatty acids. J. Agric. Food Chem. 54, 1238- 1242 https://doi.org/10.1021/jf052521h
  16. Solfrizzi, V., Panza, F., Torres, F., Mastroianni, F., Del Parigi, A., Venezia, A. and Capurso, A. (1999) High monounsaturated fatty acids intake protects against agerelated cognitive decline. Neurology 52, 1563-1569 https://doi.org/10.1212/WNL.52.8.1563
  17. Lee, J.-H., Lee, S.-Y., Lee, K.-S., Jang, H.-J., Lee, K.-H., Hahn, T.-R. and Paik, Y.-S. (2004) Prolyl endopeptidase inhibitors from the leaves of Ginkgo biloba. Planta Med. 70, 1228-1230 https://doi.org/10.1055/s-2004-835856
  18. Kimura, K., Kawaguchi, N., Yoshihama, M. and Kawanishi, G.. (1990) Staurosporine, a prolyl endopeptidse inhibitor. Agric. Biol. Chem. 54, 3021-3022 https://doi.org/10.1271/bbb1961.54.3021
  19. Song, K.-S. and Raskin, I. (2002) A prolyl endopeptidaseinhibiting benzofuran dimer from Polyozellus multiflex. J. Nat. Prod. 65, 76-78 https://doi.org/10.1021/np010194b
  20. Park, Y.-S., Jang, H.-J. and Paik, Y.-S. (2005) Prolyl endopeptidase inhibitory activity of ursolic and oleanolic acids from corni fructus. Agric. Chem. Biotechnol. 48, 207- 212
  21. Haag, M. (2003) Essential fatty acids and the brain. Can. J. Psychiatr. 48, 195-203 https://doi.org/10.1177/070674370304800308